硫糖铝片联合双歧杆菌三联活菌胶囊治疗腹泻型肠易激综合征的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the clinical effect of Sucralfate Tablets combined with Bifidobacterium Triple Viable Capsule in the treatment of diarrhea type irritable bowel syndrome.Methods220 patients with diarrhea type irritable bowel syndrome who were treated in our hospital from February 2011 to February 2016 were selected and randomly divided into the experimental group and the control group,110 cases in each group.The control group was treated with Bifidobacterium Triple Viable Capsule,the experimental group was treated with Sucralfate Tablets on the basis of the control group.The two groups were treated for 6 cycles,and after 4 weeks of withdrawal,the clinical efficacy of the two groups was observed.ResultsThe total effective rate of the experiment group was 92.73%,which was higher than 80.91%of the control group,with significant difference (P＜0.05).The abnormal clinical symptoms after treatment in the experimental group were significantly relieved,compared with the control group,the difference was statistically significant(P＜0.05).There was no significant difference in the incidence rate of adverse reactions between the two groups(P＞0.05).The recurrence rate at 1 months and 2 months of the experimental group was 0.91%and 4.55%,which was significantly lower than that of the control group(5.45%and 12.73%),with significant difference(P＜0.05).ConclusionSucralfate Tablets combined with Bifidobacterium Triple Viable Capsule in the treatment of diarrhea type irritable bowel syndrome is safe and effective,the clinical symptoms of the patients can be significantly improved,and the adverse reactions is less,and it is worthy of clinical promotion and application.

Key words： Sucralfate Tablets Bifidobacterium Triple Viable Capsule Diarrhea type irritable bowel syndrome Clinical curative effect

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIE Jun-feng
	HU Yun-shu

Cite this article:

XIE Jun-feng,HU Yun-shu. Clinical effect of Sucralfate Tablets combined with Bifidobacterium Triple Viable Capsule in the treatment of diarrhea type irritable bowel syndrome[J]. 中国当代医药, 2017, 24(14): 109-111.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I14/109

[5]	王崇强，李庭赞，徐胡根.匹维溴铵、培菲康联合黛力新治疗腹泻型肠易激综合征的疗效观察[J].皖南医学院学报，2015，19（4）：366-369.
[6]	吴银伟.双歧三联活菌胶囊对腹泻型肠易激综合征患者肠道菌群的影响及疗效观察[J].中国微生态学杂志，2014，26（4）：438-440.
[7]	孙建民.双歧杆菌四联活菌片联合参苓白术丸治疗小儿非感染性腹泻的疗效及对血清IL-6、IL-17的影响[J].现代中西医结合杂志，2016，25（2）：155-157.
[8]	孙铭.双歧杆菌乳杆菌三联活菌片治疗肠易激综合征40例[J].新乡医学院学报，2011，28（4）：509-510.
[9]	吴胜智，郑卫方，卢中华.双歧杆菌三联活菌胶囊联合乳果糖治疗便秘型肠易激综合征观察[J].药物流行病学杂志，2015，24（1）：6-8.
[10]	韩金平.氟哌噻吨美利曲辛联合双歧三联活菌胶囊治疗腹泻型肠易激综合征的疗效观察[J].中国药物与临床，2011，11（S1）：19-20.
[11]	姚毓洲，翁钦杰，林友光，等.培菲康胶囊治疗肠易激综合征临床疗效观察[J].中国医药指南，2012，10（8）：538-539.
[13]	任乃刚，陈伟，彭勃，等.整肠生的作用机制及临床应用[J].中国临床药理学杂志，2013，29（9）：716-717，720.
[14]	郝靖欣，韩麦，段丽萍，等.肠易激综合征患者肠道黏膜炎症与精神障碍的关系[J].中华医学杂志，2012，92（32）：2247-2251.
[1]	周渝，郑仕诚，付万朝，等.双歧杆菌三联活菌片治疗地震灾区（汶川）腹泻型肠易激综合征患者的多中心临床研究[J].四川医学，2012，33（2）：193-195.
[2]	吴蓉，姒健敏，王侃，等.匹维溴铵联合双歧杆菌三联活菌和多塞平治疗腹泻型肠易激综合征的疗效分析[J].中国医师进修杂志，2011，34（19）：1-4.
[3]	张东丽，伏亦伟，孔宏芳，等.氟哌噻吨美利曲辛联合双歧杆菌三联活菌对腹泻型肠易激综合征患者焦虑抑郁和免疫功能的改善作用[J].中国医药导刊，2015，11（12）：1255-1257.
[4]	曾雯君，汪琳，施义方.双歧杆菌三联活菌联合参苓白术颗粒治疗腹泻型肠易激综合征疗效分析[J].中国医师进修杂志，2013，36（6）：294-296.
[12]	Patel MM，Amin AF.Process，optimization and characterization of mebeverine hydrochloride loaded guar gum microspheres for irritable bowel syndrome[J].Carbohydrate Polymers，2011，86（2）：536-545.
[15]	Quigley EM，Abdel-Hamid H，Barbara G，et al.A global perspective on irritable bowel syndrome：a consensus statement of the world gastroenterology organisation summit task force on irritable bowel syndrome[J].J Clin Gastroenterol，2012，46（5）：356-366.